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Abstract
Background: We present our experience of therapeutic vaccination using dendritic cells (DC)
pulsed with autologous tumor antigens in patients with advanced melanoma.
Methods: Twenty-one pretreated advanced melanoma patients were vaccinated with autologous
DC pulsed with 100 μg/ml of autologous-tumor-lysate (ATL) or – homogenate (ATH) and 50 μg/
ml of keyhole limpet hemocyanin (KLH). The first 8 patients were treated subcutaneously or
intradermally with immature-DC (iDC) (range 4.5 – 82 × 106) and the remaining 13 intradermally
with in vitro matured DC (mDC) (range 1.2–26 × 106). Subcutaneous interleukin-2 (3 × 106 IU) was
administered from days 3 to 7 of each treatment cycle.
Results: Three of the 8 iDC patients obtained stabilizations (SD), each of 6 months' duration. The
13 mDC patients showed 1 complete response (8 months), 1 partial response (3 months), 2 mixed
responses (6 and 12 months) and 3 SD (9, 7+, and 3+ months). Overall responses (OR) were
observed in 4/21 (19%) patients, or 4/13 (30.7%) considering mDC treatment only. 10/21 (47.6%)
patients showed non progressive disease (NPD), with 7/13 (53.8%) cases of NPD for mDC-treated
patients. No major toxicities were observed. The positive delayed-type hypersensitivity (DTH) test
to ATL/ATH and/or KLH correlated with increased overall survival (OS). Median OS was 24
months (range 3 – 45) for the 10 DTH-positive (1 iDC and 9 mDC) and 5 months (range 3–14) for
the 11 DTH-negative patients (P < 0.001). The in vitro evaluation of gamma IFN-secreting T-cells in
10 patients showed good correlation with both DTH (75%) and clinical outcome (70%).
Conclusion: Vaccination using DC pulsed with ATL/ATH and KLH in advanced melanoma patients
is well tolerated and can induce a clinical response, especially when mDC are used. Successful
immunization, verified by positive DTH, leads to longer survival.
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In the complex interaction of relationships that exist
between the immune system and cancer, therapeutic vac-
cination can be considered as a valid approach to over-
coming the established state of immunotolerance
between the two systems [1,2].
The use of dendritic cells (DC) derived from peripheral
blood precursors and pulsed with tumor antigens forms
the basis of experimental and clinical trials on antitumor
vaccinations [3,4]. Although numerous clinical studies
have reported interesting objective regressions, case series
are often small with limited overall response rates [5]. A
recent review on antitumor vaccines, especially with
regard to melanoma, attributed an overall response (OR)
of 3.8%, with an encouraging 7.1% for DC vaccines [6].
Although OR rates for vaccination are somewhat limited,
results obtained with DC vaccinations can be considered
promising, also because of the low toxicity observed [7].
The majority of these studies have aimed at demonstrat-
ing immunization against a single or a cocktail of well
defined antigens and, considering the potentially enor-
mous number of antigens presented by the tumor and
remodelled over time [8,9], it is rather surprising that any
clinical responses have been observed at all [10-13]. How-
ever, in addition to the fundamental choice of antigens,
the generation, cell culture, maturation status, and admin-
istration modalities of DC represent other critical steps
needed for the good outcome of therapeutic vaccination.
At present, most authors use leukapheresis as source of
DC [14-16]. Furthermore, the initial use of immature DC
(iDC) has been replaced by that of DC matured in vitro
(mDC) [17,18]. Conversely, the number of DC to admin-
ister, vaccination scheduling and duration, and routes of
administration have still to be defined [19-21].
Another critical and much discussed issue is the clinical
use of cytokines as vaccination adjuvants. In particular, it
is not clear whether the administration of interkeukin-2
(IL-2) is necessary, useful, or counterproductive for clini-
cal results [22-26].
It is also difficult to carry out a critical review of DC stud-
ies because the evaluation criteria used (WHO, RECIST)
do not adapt well to some clinical situations obtained
with vaccination [27,28]. The problem could, in part, be
resolved by carrying out immunomonitoring, which is
feasible for vaccinations with one or a small number of
defined antigens, but much more complex when unde-
fined antigen complexes are used [29].
We present an in-depth description of a phase I-II study of
therapeutic vaccination using DC pulsed with autologous
tumor lysate (ATL) or homogenate (ATH) and with key-
hole limpet hemocyanin (KLH) in advanced melanoma
patients. The study was begun in 2001 and was thus influ-
enced by our own experience and by that of other authors.
Methods
Patients
From August 2001 to September 2005, 21 patients with
advanced melanoma were entered onto the vaccination
protocol using autologous DC pulsed with ATL or ATH
and KLH. Eight patients were treated with immature DC
(iDC) and 13 with mature DC (mDC). Inclusion criteria
were age < 70 years, histologically confirmed diagnosis of
melanoma, measurable disease (excluding brain metas-
tases), previous removal of one or more metastatic lesions
from which a sufficient quantity of ATL/ATH was
obtained for at least 6 vaccinations, Performance Status
(PS) ≤ 2 (according to ECOG criteria), life expectancy
more than 4 months.
Treatment
The first 8 patients were treated with iDC (range 4.5 – 82
× 106) via subcutaneous or intradermal injection with an
insulin needle. Several inoculations were made (average
6–8) near the groin or the armpit in non metastatic, non
lymphadenectomized sites. A further 13 patients were
treated with intradermal mDC (range 1.2–26 × 106) alone
following the abovementioned criteria, but with 8-10
inoculations. Subcutaneous IL-2 (Chiron, Milan, Italy)
3,000,000 IU/day was administered about 48 hours after
each vaccination for 5 consecutive days. The first 4 vacci-
nations were carried out at intervals of 15 days and once a
month thereafter.
Clinical evaluation (in partial acordance with RECIST cri-
teria [28]), and delayed-type hypersensitivity (DTH)
assessment were carried out before the first vaccination,
after the 4th vaccination, and every 2 vaccinations thereaf-
ter. The disappearance of, or an important reduction in
pre-existing lesions in concomitance with disease progres-
sion in other sites, was considered as a mixed response
(MR). If progression did not compromise the patient's
general conditions, several more vaccinations were carried
out until progression was irrefutably documented. The
best response obtained was considered for evaluation pur-
poses. Toxicity or adverse events were assessed after each
vaccine administration.
The study protocol was reviewed and approved by the
local Ethics Committee, in accordance with ethical stand-
ards laid down in the 1964 Declaration of Helsinki, and
authorized in July 2001 by the Italian Ministry of Health.
All patients gave their informed written consent to receive
treatment.Page 2 of 11
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Surgically removed tumor samples were mechanically dis-
persed to create a single-cell suspension. The largest pieces
were incubated at 37°C in enzyme mix (collagenase
0.1%, hyaluronidase 0.01%, DNAse 0.1%, Sigma, Milan,
Italy) in RPMI 1640, (PAA Laboratories GmbH, Pasching,
Austria) for 3 hours. At the end of incubation the pellets
were washed 3 times with PBS and incubated for at least
20 minutes in sterile distilled water. Lysis was monitored
by light microscope. Larger particles were removed by cen-
trifugation (10 min at 600 g) and the supernatant was
passed through a 0.2-μm filter. Protein contents were
determined and aliquots were stored at -80°C until use,
after verification of sterility.
Autologous Tumor Homogenate (ATH) preparation
In some cases, the surgically removed tissue was stored at
-80°C because the decision to vaccinate had still not been
taken. Frozen tissue fragments were pulverized in a dis-
membrator after immersion in liquid nitrogen. Pulverized
tissue was then suspended in PBS. After centrifugation, the
supernatant was treated as described above.
DC generation
DC were prepared from peripheral blood monocytes
(PBMC) obtained by leukapheresis without previous
mobilization. Five to nine liters of blood were processed
in each collection. PBMC were purified on Ficoll-Paque.
An aliquot of PBMC was utilized immediately for DC gen-
eration and the rest was frozen in bags for use at a later
date (4–5 bags/each collection).
PBMC were incubated in tissue culture flasks with CellGro
DC medium (Cell Genix, Freiburg, Germany) at 10 × 106
cells/ml for 2 h. The non-adherent cells were discarded
and the adherent cells were incubated in CellGro DC
medium containing 1000 IU/ml rhIL-4 (Cell Genix,
Freiburg, Germany) and 1000 IU/ml rhGM-CSF (Scher-
ing-Plough, Milan, Italy) for 7 days to generate a DC-
enriched cell population. On day 6, 90% of the DC cul-
ture was pulsed with ATL/ATH (100 mg/ml), while the
remaining 10% was pulsed with KLH (50 mg/ml). Both
cultures were then incubated overnight. On day 7, the
cells were defined as immature DC (iDC). After eliminat-
ing the previous culture medium, pulsed iDC were cul-
tured for a further 2 days with a cocktail of cytokines
(TNFα, IL-1β, IL-6, Endogen, Pierce Biotechnology, Rock-
ford, USA; PGE2, Cayman Chemical, Ann Arbor, MI,
USA). On day 9 they were defined as mature DC (mDC).
iDC or mDc were removed, washed and suspended in
sterile saline for therapeutic infusion into the patient
(iDC, range 4.5 – 82 × 106; mDc, range 1.2–26 × 106).
Phenotype analysis
iDC and mDC phenotypes were determined by single or
two-color fluorescence analysis in cells labelled with
monoclonal antibodies (mAbs) and fixed in paraformal-
dehyde 2%. The fluorescence was analyzed by a FACS
Vantage flow cytometer (Becton Dickinson, Milan, Italy).
mAbs specific for human CD1a, CD14, CD80, CD86,
HLA-DR (Becton Dickinson), CD83 (Immunotech, Mar-
seille, France) and CCR7 (BD Pharmingen, Milan, Italy)
were used.
In Vivo monitoring
ATL or ATH (10 μg) and KLH (5 μg) were each suspended
in 500 μl of PBS and injected intradermally into the fore-
arm of the patient. PBS alone was used as negative control.
In Vitro immunomonitoring
Evaluation of interferon-gamma-secreting cells
The patient's lymphocytes were collected and frozen
before the first vaccination, after 4–6 vaccinations, and
after 8–13 vaccinations. After thawing, 10 × 106 lym-
phocytes were stimulated in vitro overnight with ATL/ATH
and 10 × 106 with KLH. Positive and negative controls
were always included. Interferon-gamma (IFN-γ) secreting
cells were detected using the IFN-γ Secretion Assay Cell
Enrichment and Detection Kit (Miltenyi Biotec, Bergisch
Gladbach, Germany) according to the manufacturer's
instructions.
Statistical evaluations
Survival time was calculated as the time between the date
of the first cycle of therapy and the date of death from any
cause. Survival curves were traced by the Kaplan-Meier
method and the comparison between the two groups was
based on the Log-Rank test. A two- sided P value of 5%
was considered as significant. All analyses were performed
using the R statistical software package.
Results
Patient characteristics were as follows: 13 males, 8
females, with a median age of 52 years (range 35–75). Pre-
treatments, sites of evaluable disease, and PS are analyti-
cally described and analyzed in Table 1, together with the
HLA determination of each patient. Two patients older
than 70 years but in good general conditions were
enrolled onto the study and treated on a compassionate
basis.
The number of cells administered for each vaccination
was about 10 × 106, with a higher median for iDC (17 ×
106, range: 11–49.5) than for mDC (9.5 × 106, range: 5.9–
12.6). A total of 145 administrations (49 iDC and 96
mDC) were made.Page 3 of 11
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and mDC phenotyping was similar to that described in
the literature, and there were no relevant differences in
DC obtained from fresh or frozen tissue [4].
DC were pulsed with ATH in 9 cases, with ATH + ATL in 2
patients, and with ATL in 10 patients. During the course
of the study we decided to continue using, where possible,
only ATL-pulsed DC (ATL should, in theory, have a higher
percentage of antigenic protein).
Clinical results
In the 8 patients treated with iDC, we observed 3 stabili-
zations (SD), each of 6 months' duration, and 5 PD. Over-
all survival (OS) of the SD patients was 45, 26 and 7
months, whereas that of the PD patients ranged from 4 to
Table 1: Patient characteristics
Patient ID Sex Age (Years) PS (ECOG) HLA Site of Evaluable Disease Pretreatments
1 L.A. M 75 1 A2A32Cw4Cw6 spleen, soft tissue IFN
2 G.I. F 66 0 A24A11B44B18Bw4Bw6Cw5Cw7 pelvis CT+RT
3 M.G. M 73 1 A1A10B13B41Bw4Bw6 liver, lymph node CT
4 S.P. M 56 1 A9A32B38B55Bw4Bw6Cw3 lung, bone, lymph node BIOCT
5 G.C. M 51 0 A1A2B8B35Bw6Cw4Cw7 liver, lymph node IFN
6 Z.V. M 42 1 A1A19B51B14 lung BIOCT
7 G.L. M 56 2 A3A28B35B53Cw4 liver BIOCT
8 B.A. M 35 2 A2A9B7B15Bw6Cw3Cw7 lung, bone skin BIOCT
9 P.M. M 45 0 A1A9B17Bw4Bw6Cw3Cw4 lung, lymph node BIO, BIOCT
10 P.M. M 52 0 A11A31B14B60Bw6Cw3 kidney, adrenal gland BIOCT
11 R.L. F 46 1 A3A29B44Bw4 lung, liver, soft tissue CT
12 G.D. M 46 0 A3A28B21B35Cw4 lymph node NT
13 R.G. M 65 1 A10B8B38Bw4Bw6Cw7 lung, soft tissue BIOCT
14 T.A. F 61 1 A2A19B35B37Bw4Bw6Cw4 soft tissue CT+RT
15 B.A. F 59 2 A2A9B39B44Bw4Bw6Cw5 liver, soft tissue BIOCT, locoregional CT
16 C.P. F 39 0 A9A19B14B44Bw4Bw6Cw5 kidney, soft tissue Locoregional CT
17 O.M. M 56 1 A19A28B5B16Bw4Bw6 lung, soft tissue BIOCT
18 L.B. F 39 2 pelvis, lymph node BIOCT
19 M.J.L. F 37 0 lung, kidney, lymph node, soft 
tissue
BIOCT
20 O.G. M 65 2 A23A32 adrenal gland, lymph node, soft 
tissue
BIOCT
21 M.R. F 38 0 lymph node BIOCT
21 Viscera: 13 BIOCT
- 1 spleen 3 BIO
- 5 liver 4 CT
- 8 lung 2 Locoregional CT
- 3 kidney 2 RT
- 2 adrenal gland 1 NT
- 2 pelvis
2 Bone
8 Lymph node
9 Soft tissue
PS (ECOG) = performance status according ECOG; CT= chemotherapy; RT= radiotherapy;
BIO=Immunotherapy (Interferon, Inteleukin-2); BIOCT= chemotherapy+immunotherapy; NT= no treatment.
Male/Female 13/8
Median age 52 years (35–75).
P.S.: 0 = 8 ; 1 = 8; 2 = 5Page 4 of 11
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both ATH and KLH in the patient with the longest survival
(median OS 7.5 months, range 4–45). A weak positivity to
only KLH was seen in the patient with a 26-month sur-
vival, whereas no response was observed in the remaining
patients (Table 3A).
In the 13 mDC-treated patients, one complete response
(CR) of 8 months' duration (OS = 32+ months), one par-
tial response (PR) lasting 3 months (OS = 14 months) and
2 mixed responses (MR) of 12 and 6 months' duration
(OS = 28+ and 22 months, respectively) were obtained.
There were also 3 SD lasting 7+, 6 and 3+ months (the
third patient is still undergoing treatment) (OS = 7+, 14
and 3+ months, respectively) and 6 PD with a median OS
of 5.5 months (range 3–20). Median OS was 8 months
(range 3–32+).
Patient no. 12 (46-year old man), who had numerous
metastatic abdominal and pelvic lymph node localiza-
tions, obtained a CR of 8 months, and was the only
patient who had not received previous treatment. He
developed vitiligo (Figure 1) and the DTH test confirmed
a good response to ATL and KLH. Baseline and first-eval-
uation CT scan images are shown in Figure 2. Patient no.
9 rapidly obtained a PR for lung and lymph node lesions
but developed brain metastases after only 3 months. MR
was observed in patient nos. 10 and 14, in whom subcu-
taneous and lymph node metastases disappeared and
reappeared for 6 and 12 months, respectively. These
patients showed positive DTH for KLH, the former also a
strong positive reaction for ATL. All data are analytically
reported in Table 3B.
Table 2: Surface expression of DC markers in infused DC*
Marker iDC
Median % (range)
mDC
Median % (range)
CD1A 15.5 (0 – 58) 7 (0 – 77)
CD14 0 (0 – 17) 4 (0 – 67)
CD80 0 (0 – 25) 62 (2 – 98)
CD83 0 (0 – 25) 47 (2 – 86)
CD86 30 (0 – 90) 71 (5 – 96)
HLA-DR 51.5 (3 – 95) 78 (13 – 100)
CCR7 2.5 (0 – 47)§ 45 (1 – 91)
iDC, immature dendritic cells; mDC: mature dendritic cells.
§value calculated on 3/8 patients vaccinated with iDC.
*Data represent the percentage of positive cells out of the total 
number of DC analyzed.
Table 3A: Immunological and clinical response in patients vaccinated with iDC
Patient ID No. of 
Vaccinations
Antigens 
(Type of 
Lysate)
Median 
No. of 
Administe
red Cells × 
106 (range)
DTH Best Response 
after 4 or More 
Vaccinations.
Vitiligo Clinical 
Response
Response 
Duration 
(Months)
Overall 
Survival 
(Months)
L/H KLH
1 L.A. 8 H 49.5 (15 – 
82)
+ + SD 6 45
2 G.I. 5 L 13 (4.5 – 
26)
- + SD 6 26
3 M.G. 5 L 11 (7 – 
16.2)
- - +/- SD 6 7
4 S.P. 8 L 26.5 (10 – 
43.5)
- - PD - 8
5 G.C. 6 L 19 (9.6 – 
32)
- - PD - 10
6 Z.V. 5 L/H 11.3 (6.4 – 
21.5)
- - PD - 4
7 G.L. 6 H 22.6 (16.4 – 
48)
- - PD - 5
8 B.A. 4 H 15 (12 – 51) - - PD - 5
No. of 
Patients
Administrati
on Route
Site No. of 
Inoculatio
ns
8 iDC 4 i.d. and 4 s.c. 6 inguinal and 
2 axillary
6–8
DTH, delayed-type hypersensitivity; L, autologus lysate; H, autologous homogenate; KLH, keyhole limpet hemocyanin; SD, stabilization; PD, 
progressive disease.
i.d., intradermal; s.c., subcutaneousPage 5 of 11
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which increased to 30.7% (4/13) when only the results
obtained with mDC were considered. The overall percent-
age of patients who did not progress was 47.6% (10/21),
rising to 53.8 % (7/13) for those treated with mDC. Our
data do not seem to have been influenced by age, sex, or
HLA distribution (in 8/10 patients there was a distribu-
tion of 2 patients for each of the principle alleles, A1, A2,
A3 and A11). There does not appear to be any specific cor-
relation between response and site of disease or type of
pretreatment, although it should be remembered that the
only patient who obtained a CR had not been pretreated.
Futhermore, the number of cells injected would not
appear to affect response.
Conversely, initial PS may have exerted an influence on
response; all 5 patients with PS = 2 at baseline progressed.
Clinical response obviously correlated positively with OS:
11 patients with progressive disease (PD) had a median
OS of 5 months (range 3–20), whereas the 10 who did not
progress had a median OS of 21 months (range 3+ – 45).
Toxicity
Apart from swelling, redness and pruritus around the site
of inoculation, no noteworthy toxicities or side-effects
were observed. A low fever with mild flu-like symptoms
(grade 1–2) accompanied the administration of IL-2 from
the 3rd to the 7th day of treatment. No autoimmune phe-
nomena were observed apart from the onset of vitiligo in
Table 3B: Immunological and clinical response in patients vaccinated with mDC
Patient ID No. of 
Vaccinatio
ns
Antigens 
(Type of 
Lysate)
Median 
No. of 
Administe
red Cells × 
106 (range)
DTH Best Response 
after 4 or More 
Vaccinations
Vitiligo Clinical 
Response
Response 
Duration 
(Months)
Overall 
Survival 
(Months)
L/H KLH
9 P.M. 7 L 11.4 (9 – 
24.1)
- - PR 3 14
10 P.M. 15 L 15 (2.8 – 
24)
++ ++++ MR 6 22
11 R.L. 10 H 9.5 (4 – 
13.4)
- ++ SD 9 14
12 G.D. 16 L/H 12.6 (2.8 – 
20.8)
++ +++ + CR 8 32+
13 R.G. 4 H 9.3 (8 – 26) - +++ PD - 8
14 T.A. 13 H 9 (1.2 – 12) - ++ MR 12 28+
15 B.A. 4 H 5.9 (3.7 – 
12)
- - PD - 7
16 C.P. 6 H 7.8 (1.6 – 
15)
- ++ PD - 20
17 O.M. 4 H 11.5 (10 – 
21)
- - PD - 5
18 L.B. 4 L 12.5 (10 – 
15.5)
- - PD - 3
19 M.J.L. 8 L 6 (2.2 – 10) + +++ + SD 7+ 7+
20 O.G. 5 L 10 (8.8 – 
12.3)
- - PD - 3
21 M.R. 4 L 9.2 (8 – 10) + ++ SD (u.t.) 3+ 3+
No. of 
Patients
Administr
ation 
Route
Site No. of 
Inoculatio
ns
13 mDC 13 i.d. 10 inguinal 
and 3 
axillary
8–10
DTH, delayed-type hypersensitivity; L, autologous lysate; H, autologous homogenate; KLH, keyhole limpet hemocyanin.
PD, progressive disease; MR, mixed response; SD, stabilization; PR, partial response; CR, complete response; u.t., undergoing treatment.
i.d., intradermal; s.c., subcutaneousPage 6 of 11
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third patient.
In Vivo immunomonitoring
Amongst the 10 patients with non progressive disease
(NPD), only 2 had completely negative DTH reactions for
both KLH and ATL/ATH, whereas the 5 patients who
developed a response to ATL/ATH were all responders.
Correlating this with OS, it can be seen that, amongst
patients with a positive DTH reaction (10 patients, 8 of
whom had NPD), median survival was 24 months (range
3+-45), whereas those with negative DTH (11 patients, 2
of whom had NPD), had a median OS of 5 months (range
3–14). The actuarial curve of survival in relation to a pos-
itive or negative DTH reaction shows that 24-month OS
was 51% in DTH+ patients compared to 0% in DTH-
patients (P < 0.001) at a median follow-up of 32 months
(Figure 3). None of the patients who began treatment
with a PS of 2 showed a positive DTH test.
In Vitro immunomonitoring
In vitro immunomonitoring was performed by evaluating
the number of lymphocytes in peripheral blood that are
capable of producing gamma-IFN after stimulation with
KLH and ATL/ATH. The test was only commercialized
recently and was carried out on 10 patients (1 treated with
iDC and 9 with mDC).
Clinical responses in 7 patients corresponded with the
indications of the test (70%): positivity was correlated
with NPD in 4 cases and with PD in 3 patients. Compar-
ing the results from the in vitro test with those of DTH
stimulation using both KLH and ATL/ATH, overall con-
cordance was 75% (Table 4).
Discussion
The practice of antitumor vaccination with DC has
brought with it new hope, especially for patients with
melanoma, who obtain unsatisfactory results from tradi-
tional therapies [30,31]. The high number of known
tumor antigens makes melanoma a good target for vac-
cine therapy [8]. DC vaccination is generally easy to
administer and induces low toxicity, but studies pub-
lished to date are difficult to compare with each other
because of the small cases series involved, the limited
number of clinical responses observed, and the numerous
methodologies of DC preparation used: Cranmer, in fact,
recently listed up to 12 possible variations in culture
methodology and treatment modalities [32].
Crucial issues such as the best antigens or the most effec-
tive evaluation criteria to use have still to be clarified. DC
derived from peripheral blood rather than from bone
marrow tend to be used and it has been seen that mDC are
undoubtedly better at migrating to regional lymph nodes
and are more effective at determining an immunological
and clinical response than iDC [14,33,34]. It has also
recently been reported that intradermal administration
results in a higher DC migration than subcutaneous injec-
tion [21,35].
However, one of the main problems of vaccination ther-
apy remains the type of antigens to use. Pulsing DC with
known single peptides enables us to accurately monitor
immunization, but literature results highlight poor, short-
term clinical responses, probably due to tumor escape
[36,37]. Whilst pulsing with tumor extracts (lysate, apop-
totic bodies, heat shock proteins, etc.) theoretically
implies that all tumor antigens are represented, it also
Onset of vitiligo in patient no.Onset of vitiligo in patient no.12 who had CR after treatment with mDCFigure 1
Onset of vitiligo in patient no.12 who had CR after treatment 
with mDC.
Baseline and post 4th vaccination CT scan of patient no. 12, treated with mDCFigure 2
Baseline and post 4th vaccination CT scan of patient no. 12, 
treated with mDC. The patient had an 8-month CR of the 
abdominal soft tissue lesions.Page 7 of 11
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Actuarial curves of overall survival (OS) based on DTH resultsFig re 3
Actuarial curves of overall survival (OS) based on DTH results. Eleven patients had negative DTH with a median OS of 5 
months and no survival at 24 months. Ten patients had positive DTH (for ATL/ATH and/or for KLH) and a median OS of 24 
months, with 50% still alive after 2 years (P < 0.001).
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requires sizeable quantities of tumor tissue, and results in
DC being loaded with a large number of other non anti-
genic proteins that could reduce, in terms of percentages,
the efficacy of the exposure [6,38-41]. Novel methods of
pulsing with tumor RNA or with a selection of RNA anti-
gens could perhaps result in increased immune efficacy,
especially if we bear in mind the large number of
melanoma-restricted genes that have already been identi-
fied and codified [9,42].
Clinical evaluation also poses a problem. There is a grow-
ing need to modify RECIST criteria, widely used in oncol-
ogy, when assessing clinical responses in vaccine therapy,
e.g. to define mixed responses or responses that occur after
an initial progression. Once a vaccine strategy has been
clarified or better defined, a modified integrated system of
clinical evaluation will be needed [43].
New strategies must also be sought to overcome tumor
immunosuppression [44,45]. The use of lymphoablative
chemotherapy has been hypothesized to reduce or elimi-
nate the component of T-regulator lymphocytes before
vaccination [46-49]. Studies in this area could also clarify
the still controversial role of IL-2 as a vaccine adjuvant
[50-53] and could help to provide valuable information
about new molecular targets or cytokines [54,55].
Recent publications would seem to indicate that the pres-
ence and/or activation of specific lymphocytes induced by
immunostimulation correlates positively with survival
[56-59]. Our results concur with this finding and also
indicate the need for a better selection of patients, espe-
cially in view of the fact that poor PS would seem to cor-
relate with no clinical or immunological response.
Patients with minimal residual disease or evidence of
probable immunocompetence can be considered candi-
dates for controlled vaccine trials [60,61].
Table 4: In vitro immunomonitoring (Miltenyi Test): comparison between IFN-γ secreting lymphocytes after stimulation with KLH and 
ATL/ATH, and DTH test and clinical outcome
Patient ID Stimulation Baseline After 4/6 
Vaccinations
After 8/13 
Vaccinations
DTH Clinical 
Response
4 S.P.a KLH 0 0 Negative PD
L 0 0 Negative
9 P.M.b KLH 0 Negative PR
L 0 Negative
10
P.M.b
MR
KLH 0 0 186 Positive
L 0 0 0 Positive
12 
G.D.b
CR
KLH 133 1238 2253 Positive
L 56 456 13405 Positive
14 T.A.b KLH 4 356 73 Positive MR
H 0 0 0 Negative
16 C.P.b KLH 0 103 Positive PD
H 0 0 Negative
18 L.B.b KLH 264 110 Negative PD
L 0 0 Negative
19 
M.J.L.b
SD
KLH 0 0 Positive
L 0 0 Positive
20
O.M.b
PD
KLH 0 0 Negative
L 0 0 Negative
21 
M.R.b
SD
KLH 0 99 Positive
L 0 292 Positive
DTH, delayed-type hypersensitivity; L, autologous tumor lysate; H, autologous tumor homogenate; KLH, keyhole limpet hemocyanin.
a = pts treated with iDC.
b = pts treated with mDC.
bold = data corresponding to testPage 9 of 11
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pulsed with KLH and ATL/ATH is an experimental
approach and still requires numerous adjustments and
verifications, it would seem to be practicable, non toxic,
and most importantly, effective in prolonging OS if
administered in a subgroup of patients who show immu-
noreactivity.
Abbreviations
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